(Q41396716)

30 September 2017

1 reference

title

Diagnosis, prognosis, and standard treatment of multiple myeloma (English)

1 reference

30 September 2017

Boccadoro M

1

1 reference

30 September 2017

Pileri A

series ordinal

2

1 reference

30 September 2017

language of work or name

1 reference

1 February 1997

1 reference

Hematology / Oncology Clinics of North America

30 September 2017

published in

1 reference

30 September 2017

volume

11

1 reference

30 September 2017

issue

1

1 reference

30 September 2017

page(s)

111-131

1 reference

Occurrence of monoclonal components in general practice: clinical implications

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Chemotherapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

VAD-based regimens as primary treatment for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Combination therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Who benefits from high-dose therapy for multiple myeloma?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Single-dose intravenous melphalan in advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Bone scintigraphy in plasma-cell myeloma. A prospective study of 70 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Serum beta2microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Chemotherapy of myeloma: drug combinations versus single agents, an overview, and comments on acute leukemia in myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Mouse myeloma. A model for studies of cell kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

CD3‐induced T‐cell activation in the bone marrow of myeloma patients: major role of CD4+ cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

A new prognostic system for multiple myeloma based on easily available parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Conventional induction treatments do not influence overall survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Monitoring of a long survival myeloma patient

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Evaluation of serum β 2-microglobulin as a prognostic indicator in myelomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

N- and K-ras oncogenes in plasma cell dyscrasias.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Chemotherapy of myeloma: Southwest Oncology Group studies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Oral dosage of melphalan and response to treatment in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Neopterin as a marker for activated cell-mediated immunity: application in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Staging systems for multiple myeloma: a comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Intensive treatment of multiple myeloma and criteria for complete remission

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Identification of early plasma cells in peripheral blood and their clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

High proportions of VLA-5- immature myeloma cells correlated well with poor response to treatment in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

A new phenotypic classification of bone marrow plasmacytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

"Benign" monoclonal gammopathy--after 20 to 35 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, vincristine, prednisone, and BCNU

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Radiography and bone scintigraphy in multiple myeloma: a comparative analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Results of the MRC myelomatosis trials for patients entered since 1980

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Prognostic features in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Diagnostic value of the concentration of M-component in initial classification of monoclonal gammopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Multiple myeloma: MR patterns of response to treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Magnetic resonance imaging in the staging of solitary plasmacytoma of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukaemia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Ras oncogene mutation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Multiple myeloma: 'early' plasma cell phenotype identifies patients with aggressive biological and clinical characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Treatment of multiple myeloma with M-2 protocol and without maintenance therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Dose intensity analysis of melphalan and prednisone in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Reassessment of the relationship between M-protein decrement and survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Argyrophilic nucleolar organizer region counts and prognosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Human myeloma: kinetics of the remission phase

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Cytogenetic findings in 200 patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Bence Jones proteins: malignant or benign?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Early disappearance of murine plasmocytoma stem cells in long-term bone marrow culture

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

The value of magnetic resonance imaging in screening myeloma lesions of the lumbar spine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Treatment of multiple myeloma: a randomized study of three different regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Autopsy-documented cure of multiple myeloma 14 years after M2 chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Comparison of bone scintigraphy and radiography in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970418-4

7 January 2021

10.1016/S0889-8588(05)70418-4

Identifiers

DOI

1 reference

30 September 2017

1 reference